Drug target to halt progression of Parkinson’s disease identified
Scientists have shown that trapped LC3B protein in brain cells enables Parkinson's disease to spread, presenting a drug target.
List view / Grid view
Scientists have shown that trapped LC3B protein in brain cells enables Parkinson's disease to spread, presenting a drug target.
A new gene therapy that introduced SynCav1 to the brains of Alzheimer's mouse models was shown to preserve neuronal and synaptic plasticity.
A novel sensitive label-free imaging method has been developed to visualise brain samples using an FxClear-based tissue clearing technique.
Oral doses of a new drug named CA administered to mouse models led to improvements in Alzheimer's disease, including memory.
Researchers have developed a stem cell therapy that could treat the damage caused by dementia by launching a repair response.
A study has shown that treatments to reduce levels of hydrogen sulphide (H2S) in the brain may help to prevent dementia.
Scientists have visualised the spatial and temporal distribution of neural stem cell activation in zebrafish models.
Researchers have shown that miR-29 can control brain maturation in mammals, presenting a target for autism, epilepsy and other conditions.
Researchers have revealed that the protein ALYREF promotes the effects of the neuroblastoma gene, MYCN, making it a target.
The polymerised form of oestrogen has shown success in mice at preventing further damage to the spinal cord after injury.
Promising results have been shown in an animal model of Alzheimer's disease treated with zinc finger protein transcription factors.
A synthetic cannabinoid has shown promise as a treatment for involuntary tremors by activating astrocytes in mouse models.
Scientists have developed a model of the early stages of Alzheimer's disease in rhesus macaques to better test new treatments.
Researchers have reported that nano-micelles can be used to efficiently deliver CRISPR-Cas9 to edit genes in the brains of mice.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.